ArticleInternational journal of nanomedicine2026
Evaluation of
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Influenza is an acute respiratory infectious disease with high transmissibility and significant pandemic potential worldwide. In recent years, traditional Chinese medicine (TCM)-based carbon dots (CDs) have emerged as promising therapeutic agents owing to their favorable biosafety profile and potent anti-inflammatory and immunomodulatory properties. The present study aimed to investigate the therapeutic effects of TCM-derived CDs on influenza A virus (IAV)-induced pneumonia, and elucidate their underlying molecular mechanisms of action. Mouse Model and Methods: A murine model of IAV-induced pneumonia was established via intranasal instillation and subsequently treated with CDs co-derived from Artemisia annua and Scutellaria baicalensis (QH-CDs). Results: The results demonstrated that, compared to the observations in the model group, treatment with QH-CDs significantly alleviated the pathological damages to lung tissue, reduced the lung index, and promoted body weight recovery. QH-CDs treatment reduced the expression of key inflammatory cytokines (IL-1β, IL-6) in lung tissue by over 60% compared to the model group (p < 0.0001). In addition, QH-CDs reduce lung viral titers by more than 70%, indicating that they have combined antiviral and anti-inflammatory effects. Transcriptomic analysis revealed that treatment with QH-CDs reversed the alterations in the expression patterns of several genes associated with immunity and inflammation. The differentially expressed genes were predominantly involved in immune regulation, cytokine activity, and inflammatory signaling pathways. The results of Quantitative Real-time polymerase chain reaction (qPCR) show that the mRNA expression levels of NLRP3, Caspase-1, and IL-1β all significantly decreased. Protein expression analyses by Western blotting further confirmed the critical role of the NLRP3 inflammasome signaling pathway in mediating the therapeutic effects of QH-CDs. Conclusion: QH-CDs therapeutic effects may be closely related to the regulation of immune responses, inhibition of inflammatory responses, and modulation of the NLRP3 signaling pathway. This study provides novel insights into the therapeutic application of TCM-derived nanomaterials for the treatment of viral pneumonia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.